Apixaban Tx cost in A-fib meets U.S. norms for reasonable value
(HealthDay)—Apixaban therapy is cost-effective for atrial fibrillation from the perspective of the U.S. health care system, according to a study published online March 29 in JAMA Cardiology.
Mar 31, 2017
0
0